Kidney injury molecule-1 (KIM-1): a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury

Huo, Wenqian; Zhang, Ke‐Qin; Nie, Zhilin; Li, Qiansheng; Jin, Fang

doi:10.1016/j.trre.2010.02.002

Cited by 93 publications

(83 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is little expression in the human normal renal tissue, but an increased expression evidently occurred when the renal tissue was injured (6). A previous study has shown that KIM-1 may participate in the process of renal tubular damage and repair, which has a protective effect on acute kidney injury and an adverse effect on chronic kidney disease (7). The expression levels of KIM-1 in urine were consistent with the levels in renal tissue (16,17).…”

Section: Discussionsupporting

confidence: 63%

“…Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention large number of experimental evidence has suggested that KIM-1 is not only a good biological indicator of acute kidney injury, but also as a functional molecule to participate in the process of renal tubular damage and repair (7). The levels of KIM-1 in renal tissue measured 2 h after injection of contrast agents evidently increased, however, until 12 h after injection of contrast agents, the injury of renal tubular epithelial cells was shown to occur in the renal tissue biopsy, which has been shown in a previous rat model of low permeability, contrast agent-induced acute injury of renal tubular epithelial cell.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention

et al. 2015

Biomedical Reports

View full text Add to dashboard Cite

Abstract. With the improvement of the skill level of coronary intervention, contrast agents are used more widely. As a result, contrast-induced acute kidney injury (CI-AKI) is currently the third leading cause of hospital-acquired AKI. Traditionally, AKI is defined by measuring an increase of the serum creatinine concentration (Scr). CI-AKI indicates impairment in renal function, which is diagnosed as an elevation in the SCr levels following intravascular injection of the contrast media. However, Scr is an insensitive indicator for detecting CI-AKI. The present study was designed to investigate whether human urinary kidney injury molecule-1 (KIM-1) is an early marker to predict CI-AKI in patients with diabetes mellitus undergoing percutaneous coronary intervention (PCI). The present study includes the general clinical data of 145 patients with diabetes mellitus who underwent PCI between March 1, 2013 and December 31, 2013. A non-ionic, low osmolarity contrast agent was used during the present study. The Scr levels and estimated glomerular filtration rate were measured prior to and within 24 and 48 h after the injection of contrast agents. Urinary samples were collected prior to and within 2, 6, 12, 24 and 48 h after the coronary interventional procedure. Simultaneously, the urinary KIM-1 values were measured using an ELISA kit. CI-AKI was diagnosed as an increase of ≥0.5 mg/dl or ≥25% in Scr concentration over baseline, 24-48 h after the procedure. In total, 19 of 145 (13.1%) patients exhibited CI-AKI. There was a significant difference (P<0.05) between the urinary KIM-1 levels measured 2, 6, 12, 24 and 48 h after the procedure and those prior to the procedure in the CI-AKI group. There was no significant difference between the Scr values measured 24 h after the procedure and those prior to the procedure. Evidently, using KIM-1 values to predict CI-AKI was <24 h earlier compared to using Scr values. The area under the receiver operating characteristic curve of KIM-1 24 h after the procedure was 0.856 and the 95% confidence interval of the corresponding area was 0.782-0.929. When the pivotal point of CI-AKI diagnosis was 6,327.755 pg/ml, the specificity was 85.7% and the sensitivity was 73.7%. Univariate analysis showed that the Scr concentration was positively correlated with the urinary KIM-1 level during the time prior to the procedure and 24 and 48 h after the procedure. In conclusion, the urinary KIM-1 may be a potential indicator for the early diagnosis of CI-AKI.

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Introductionmentioning

confidence: 99%

Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention

et al. 2015

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…10 Kidney injury molecule-1 (KIM-1) is a sensitive and specific biomarker for acute kidney injury. 11 This protein is expressed in damaged tubular epithelial cells. It possesses a single transmembrane domain and undergoes membrane-proximal cleavage, which causes the release of soluble KIM-1 ectodomain into the urine.…”

Section: Introductionmentioning

confidence: 99%

Urine Liver-Type Fatty Acid-Binding Protein and Kidney Injury Molecule-1 in HIV-Infected Patients Receiving Combined Antiretroviral Treatment Based on Tenofovir

Jabłonowska

Wójcik

Piekarska

2014

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

The aim of this study was to determine the presence of kidney tubular damage in the absence of overt evidence of glomerular dysfunction (GFR > 60 ml/min without proteinuria) in HIV-infected patients receiving antiretroviral therapy. Urine kidney injury molecule-1 (KIM-1) and liver-type fatty acid-binding protein (L-FABP) levels were measured by ELISA and expressed as a ratio to creatinine. Sixty-six patients (median age 38 years) and 10 healthy controls (median age 35.5 years) were included in the study. Patients with chronic diseases such as diabetes, hypertension, heart disease, or kidney disease were excluded from the study. All patients received tenofovir/emtricitabine combined with one of three other components, namely efavirenz, atazanavir/norvir, or lopinavir/norvir. A lower concentration of L-FABP/creatinine was observed in HIV-infected as compared to healthy individuals ( p = 0.0353); KIM-1/creatinine was also lower in comparison with healthy controls but not statistically significantly. Patients receiving efavirenz had higher levels of L-FABP/creatinine in comparison to healthy controls ( p = 0.0039). Patients with anti-HCV had higher concentrations of L-FABP/creatinine as compared to the HIV-monoinfected individuals (not statistically significant) and to healthy subjects ( p = 0.0356). All four patients with L-FABP > 17.5 lg/g creatinine were HIV/HCV coinfected. On multivariate logistic regression urine L-FABP above 5.5 lg/g creatinine was independently associated with body weight (OR = 0.93 p = 0.039). This study suggests that HIV/HCV-coinfected patients with lower body weight treated with tenofovir may be at an increased risk of tubular dysfunction and should be monitored more closely. The use of protease inhibitors was not associated with an increased risk of tubular disorders.

show abstract

“…Zbudowana jest z domeny cytoplazmatycznej, domeny przezbłonowej oraz czę-ści zewnątrzkomórkowej, w której wyróżnia się domenę immunoglobulinową i mucynową [4]. kiM-1 w prawidłowych warunkach nie jest wykrywalna w nerkach ani moczu.…”

unclassified

“…Jej ektodomena zostaje wówczas odłączona od części błonowej przez metaloproteinazy i wydalona do moczu [5,6]. według Huo i wsp., kiM-1 posiada wiele cech idealnego biomarkera uszkodzenia nerek: wykrywana jest tylko w przypadku uszkodzenia cewek proksymalnych, istnieje możli-wość nieinwazyjnego oznaczania jej stężenia w moczu, stę-żenie tego białka w moczu koreluje z jego ekspresją w nerkach oraz ze stopniem ich uszkodzenia, ponadto w moczu zmienia się wcześniej niż produkty przemian azotowych i kreatyniny w krwi [4].…”

unclassified

Usefulness of urinary kidney injury molecule-1 (KIM-1) in children with idiopathic nephrotic syndrome treated with cyclosporine A

Jakubowska¹,

Zwołińska²,

Kiliś‐Pstrusińska³

2016

fmpcr

View full text Add to dashboard Cite

A, C-G katedra i klinika nefrologii Pediatrycznej uniwersytetu Medycznego we wrocławiuA -przygotowanie projektu badania, B -zbieranie danych, C -analiza statystyczna, D -interpretacja danych, E -przygotowanie maszynopisu, F -opracowanie piśmiennictwa, G -pozyskanie funduszy Wstęp. w niektórych postaciach idiopatycznego zespołu nerczycowego (iZn) stosuje się leczenie alternatywne cyklosporyną a (Csa). Poważnym objawem niepożądanym leku jest nefrotoksyczność. Poszukuje się markerów wczesnego uszkodzenia nerek, które byłyby pomocne w optymalizacji terapii. Cel pracy. określenie stężenia kiM-1 (cząsteczka uszkodzenia nerek-1, ang. kidney injury molecule-1) w osoczu i w moczu dzieci z iZn oraz ocena przydatności tego białka jako wskaźnika nefrotoksyczności Csa. Materiał i metody. Badaniami objęto 30 dzieci ze steroidozależnym (sDns) oraz steroidoopornym (srns) iZn oraz 22 dzieci zdrowych. stężenie kiM-1 oznaczono metodą immunoenzymatyczną w osoczu i moczu pobranym u dzieci z iZn przed włączeniem Csa, po 6 i 12 miesiącach. Wyniki. w grupie chorych z iZn przed włączeniem Csa stwierdzono wyższe stężenia kiM-1 w osoczu i moczu w porównaniu z grupą referencyjną. w trakcie obserwacji stężenia kiM-1 w osoczu rosły, a ich wartości różniły się istotnie między wszystkimi punktami czasowymi. stężenia kiM-1 w moczu po 6 i 12 miesiącach terapii były istotnie wyższe w porównaniu do wartości przed leczeniem, różnice stężeń tego białka w moczu po 6 i 12 miesiącach podawania leku nie były znamienne statystycznie. nie stwierdzono korelacji między stężeniem kiM-1 w moczu a stężeniem Csa w krwi, białkomoczem i eGFr. nie odnotowano znamiennych różnic między pacjentami z rozpoznanym sDns i srns pod względem analizowanych parametrów w osoczu i w moczu. Wnioski. u dzieci z iZn leczonych Csa dochodzi do zmian stężenia kiM-1 w moczu, co sugeruje przydatność oznaczeń tego białka dla monitorowania tych chorych. Słowa kluczowe: dzieci, cyklosporyna a, idiopatyczny zespół nerczycowy, kiM-1.Background. some forms of idiopathic nephrotic syndrome (ins) are treated with cyclosporine a (Csa) as an alternative method. a serious adverse effect of the drug is nephrotoxicity. to help optimize the therapy, researchers are looking for early kidney injury markers. Objectives. to determine kiM-1 (kidney injury molecule-1) plasma and urine concentrations in children with ins and to evaluate the suitability of the protein as Csa nephrotoxicity marker. Material and methods. 30 children with steroid-dependent (sDns) and steroid-resistant (srns) ins and 22 healthy children were enrolled to the study. kiM-1 plasma and urine concentrations were determined in children with ins before the administration of Csa, and then after 6 and 12 months, using the enzyme-linked immunosorbent assay (Elisa). Results. in the ins group, higher kiM-1 plasma and urine concentration were observed prior to the administration of Csa compared to the reference group. During the follow-up period, kiM-1 plasma levels were increasing, and the values varied significantly at all time points. ki...

show abstract

Kidney injury molecule-1 (KIM-1): a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury

Cited by 93 publications

References 28 publications

Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention

Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention

Urine Liver-Type Fatty Acid-Binding Protein and Kidney Injury Molecule-1 in HIV-Infected Patients Receiving Combined Antiretroviral Treatment Based on Tenofovir

Usefulness of urinary kidney injury molecule-1 (KIM-1) in children with idiopathic nephrotic syndrome treated with cyclosporine A

Contact Info

Product

Resources

About